order histories, retained contact details for faster checkout, review submissions, and special promotions.
Forgot password?
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Location
Corporate Headquarters
Vector Laboratories, Inc.
6737 Mowry Ave
Newark, CA 94560
United States
Telephone Numbers
Customer Service: (800) 227-6666 / (650) 697-3600
Contact Us
Additional Contact Details
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Forgot password?
order histories, retained contact details for faster checkout, review submissions, and special promotions.
MAPK7 / ERK5
mitogen-activated protein kinase 7
ERK5, a MAPK type protein kinase, mediates growth factor stimulated cell proliferation and muscle cell differentiation. ERK5 differs from other MAP kinases in that it contains a unique loop-12 region within the protein kinase domain which is followed by an extensive C-terminal tail with sequences indicating that it may be targeted to the cytoskeleton. ERK5 is phosphorylated and activated by MEK5 in response to osmotic shock, growth factors and oxidant stress. Activated ERK5 phosphorylates myocyte enhancer factor 2 (MEF2), Sap1, NF-kappaB and p90 ribosomal S6 kinase (RSK/MAPKAPK1). ERK (-/-) mice are defective in blood-vessel and cardiac development. At least four alternatively spliced transcript variants of this gene encoding two distinct protein isoforms, 677 and 815 amino acids, have been identified. ERK5 has been shown to participate in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.
| Gene Name: | mitogen-activated protein kinase 7 |
| Family/Subfamily: | Protein Kinase , MAPK |
| Synonyms: | MAPK7, Big MAP kinase 1, BMK-1, Erk4, ERK5, MAPK 7, PRKM7, BMK1, BMK1 kinase, ERK-5, MAP kinase 7 |
| Target Sequences: | NM_002749 NP_002740.2 Q13164 |
If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.
